464 related articles for article (PubMed ID: 24501221)
1. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.
Rossi D; Khiabanian H; Spina V; Ciardullo C; Bruscaggin A; Famà R; Rasi S; Monti S; Deambrogi C; De Paoli L; Wang J; Gattei V; Guarini A; Foà R; Rabadan R; Gaidano G
Blood; 2014 Apr; 123(14):2139-47. PubMed ID: 24501221
[TBL] [Abstract][Full Text] [Related]
2. Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.
Malcikova J; Stano-Kozubik K; Tichy B; Kantorova B; Pavlova S; Tom N; Radova L; Smardova J; Pardy F; Doubek M; Brychtova Y; Mraz M; Plevova K; Diviskova E; Oltova A; Mayer J; Pospisilova S; Trbusek M
Leukemia; 2015 Apr; 29(4):877-85. PubMed ID: 25287991
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.
Rossi D; Cerri M; Deambrogi C; Sozzi E; Cresta S; Rasi S; De Paoli L; Spina V; Gattei V; Capello D; Forconi F; Lauria F; Gaidano G
Clin Cancer Res; 2009 Feb; 15(3):995-1004. PubMed ID: 19188171
[TBL] [Abstract][Full Text] [Related]
4. Deep targeted sequencing of
Brieghel C; Kinalis S; Yde CW; Schmidt AY; Jønson L; Andersen MA; da Cunha-Bang C; Pedersen LB; Geisler CH; Nielsen FC; Niemann CU
Haematologica; 2019 Apr; 104(4):789-796. PubMed ID: 30514802
[TBL] [Abstract][Full Text] [Related]
5. TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia.
Malcikova J; Pavlova S; Kozubik KS; Pospisilova S
Hum Mutat; 2014 Jun; 35(6):663-71. PubMed ID: 24415659
[TBL] [Abstract][Full Text] [Related]
6. Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia.
Quijada-Álamo M; Pérez-Carretero C; Hernández-Sánchez M; Rodríguez-Vicente AE; Herrero AB; Hernández-Sánchez JM; Martín-Izquierdo M; Santos-Mínguez S; Del Rey M; González T; Rubio-Martínez A; García de Coca A; Dávila-Valls J; Hernández-Rivas JÁ; Parker H; Strefford JC; Benito R; Ordóñez JL; Hernández-Rivas JM
Clin Transl Med; 2021 Feb; 11(2):e304. PubMed ID: 33634999
[TBL] [Abstract][Full Text] [Related]
7. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.
Rossi D; Fangazio M; Rasi S; Vaisitti T; Monti S; Cresta S; Chiaretti S; Del Giudice I; Fabbri G; Bruscaggin A; Spina V; Deambrogi C; Marinelli M; Famà R; Greco M; Daniele G; Forconi F; Gattei V; Bertoni F; Deaglio S; Pasqualucci L; Guarini A; Dalla-Favera R; Foà R; Gaidano G
Blood; 2012 Mar; 119(12):2854-62. PubMed ID: 22308293
[TBL] [Abstract][Full Text] [Related]
8. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.
Ljungström V; Cortese D; Young E; Pandzic T; Mansouri L; Plevova K; Ntoufa S; Baliakas P; Clifford R; Sutton LA; Blakemore SJ; Stavroyianni N; Agathangelidis A; Rossi D; Höglund M; Kotaskova J; Juliusson G; Belessi C; Chiorazzi N; Panagiotidis P; Langerak AW; Smedby KE; Oscier D; Gaidano G; Schuh A; Davi F; Pott C; Strefford JC; Trentin L; Pospisilova S; Ghia P; Stamatopoulos K; Sjöblom T; Rosenquist R
Blood; 2016 Feb; 127(8):1007-16. PubMed ID: 26675346
[TBL] [Abstract][Full Text] [Related]
9. An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness.
Rigolin GM; Formigaro L; Cavallari M; Quaglia FM; Lista E; Urso A; Guardalben E; Martinelli S; Saccenti E; Bassi C; Lupini L; Bardi MA; Volta E; Tammiso E; Melandri A; Negrini M; Cavazzini F; Cuneo A
Oncotarget; 2017 Apr; 8(17):28008-28020. PubMed ID: 28427204
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E
Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699
[TBL] [Abstract][Full Text] [Related]
11. The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia.
Yuan YY; Zhu HY; Wu JZ; Xia Y; Liang JH; Wu W; Cao L; Wang L; Fan L; Li JY; Xu W
Genes Chromosomes Cancer; 2019 Jan; 58(1):43-51. PubMed ID: 30350431
[TBL] [Abstract][Full Text] [Related]
12. PRIMA-1
Jaskova Z; Pavlova S; Malcikova J; Brychtova Y; Trbusek M
Leuk Res; 2020 Feb; 89():106288. PubMed ID: 31924585
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
[TBL] [Abstract][Full Text] [Related]
14. Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations.
Rigolin GM; Saccenti E; Bassi C; Lupini L; Quaglia FM; Cavallari M; Martinelli S; Formigaro L; Lista E; Bardi MA; Volta E; Tammiso E; Melandri A; Urso A; Cavazzini F; Negrini M; Cuneo A
J Hematol Oncol; 2016 Sep; 9(1):88. PubMed ID: 27633522
[TBL] [Abstract][Full Text] [Related]
15. TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing.
Minervini CF; Cumbo C; Orsini P; Brunetti C; Anelli L; Zagaria A; Minervini A; Casieri P; Coccaro N; Tota G; Impera L; Giordano A; Specchia G; Albano F
Diagn Pathol; 2016 Oct; 11(1):96. PubMed ID: 27724982
[TBL] [Abstract][Full Text] [Related]
16. TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods.
Kantorova B; Malcikova J; Smardova J; Pavlova S; Trbusek M; Tom N; Plevova K; Tichy B; Truong S; Diviskova E; Kotaskova J; Oltova A; Patten N; Brychtova Y; Doubek M; Mayer J; Pospisilova S
Tumour Biol; 2015 May; 36(5):3371-80. PubMed ID: 25527155
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Farooqui MZ; Valdez J; Martyr S; Aue G; Saba N; Niemann CU; Herman SE; Tian X; Marti G; Soto S; Hughes TE; Jones J; Lipsky A; Pittaluga S; Stetler-Stevenson M; Yuan C; Lee YS; Pedersen LB; Geisler CH; Calvo KR; Arthur DC; Maric I; Childs R; Young NS; Wiestner A
Lancet Oncol; 2015 Feb; 16(2):169-76. PubMed ID: 25555420
[TBL] [Abstract][Full Text] [Related]
18.
Bomben R; Rossi FM; Vit F; Bittolo T; D'Agaro T; Zucchetto A; Tissino E; Pozzo F; Vendramini E; Degan M; Zaina E; Cattarossi I; Varaschin P; Nanni P; Berton M; Braida A; Polesel J; Cohen JA; Santinelli E; Biagi A; Gentile M; Morabito F; Fronza G; Pozzato G; D'Arena G; Olivieri J; Bulian P; Pepper C; Hockaday A; Schuh A; Hillmen P; Rossi D; Chiarenza A; Zaja F; Di Raimondo F; Del Poeta G; Gattei V
Clin Cancer Res; 2021 Oct; 27(20):5566-5575. PubMed ID: 34285062
[TBL] [Abstract][Full Text] [Related]
19. TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia.
Dong HJ; Fang C; Wang L; Fan L; Xu J; Wu JZ; Lu TX; Li JY; Xu W
Med Oncol; 2014 Apr; 31(4):908. PubMed ID: 24615009
[TBL] [Abstract][Full Text] [Related]
20. The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study.
De Luca G; Cerruti G; Lastraioli S; Conte R; Ibatici A; Di Felice N; Morabito F; Monti P; Fronza G; Matis S; Colombo M; Fabris S; Ciarrocchi A; Neri A; Menichini P; Ferrarini M; Nozza P; Fais F; Cutrona G; Dono M
Hematol Oncol; 2022 Dec; 40(5):962-975. PubMed ID: 35961859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
